New Online Tool Simplifies Clinical Trial Search
The Pulmonary Hypertension Association (PHA) is pleased to announce the launch of its new Clinical Trial Finder, now available in the research section of the PHA website, PHAssociation.org. PHA provides this tool to help participants learn more about ongoing PH research. The tool includes filters to narrow search results to fit an individual’s personal needs.
PHA Helps Spread Awareness of Blood Clots and Relationship to PH
The Pulmonary Hypertension Association (PHA) is pleased to join The National Blood Clot Alliance and other health care organizations around the nation to spread the word about blood clots during Blood Clot Awareness Month (BCAM) in March. This year’s theme is “Together We Can Increase Awareness and Save Lives.” BCAM’s goal is to bring
Qiana Lomax: The Importance of a Support System
“I am extremely glad I have friends and family that are helping me through this process, no one should do this alone.” “I am 21-year-old college student studying to be a Physician Assistant and I was diagnosed with Pulmonary Arterial Hypertension (PAH) on Jan. 17, 2019. I was over all completely healthy
Learning to Deal With a Chronic Illness
“When the pulmonology team met with my husband and me and tried to explain CTEPH, I simply broke down.” “I am 57 years old and was diagnosed last November at the University of Kansas (KU MED) Hospital in Kansas City with CTEPH after a large blood clot was found in my right
Updated REVEAL Risk Calculator Improves Accuracy of PAH Survival Predictions
A team of researchers has increased the accuracy of a tool used to predict survival for individuals with World Health Organization Group 1 PH (pulmonary arterial hypertension or PAH). CHEST Journal, the official publication of the American College of Chest Physicians, has published a study by Raymond L. Benza, M.D., a cardiologist at Allegheny
Second Generic Tadalafil Product Announced
Questions to Consider When Choosing Between Brand and Generic Therapy Teva Pharmaceutical Industries recently announced the launch of ALYQ ™ (tadalafil), a generic version of the drug Adcirca®. Mylan launched the first generic tadalafil in August. How an individual with pulmonary hypertension (PH) is impacted by the availability of generic therapy may depend on
Living With Two Rare Diseases
“Rare Disease Day is not just about PH; it is also a recognition of the many rare diseases for which resources and funding are often limited.” By Shan Hardwick “I have PH, caused by scleroderma. I had symptoms of a scleroderma-related syndrome for years, but no one put them together for a
CEO Update: Rare Disease Day Plays Important Role in Increased PH Awareness
Dear PH Community, The last day of February — whether it is the 28th or the 29th in a leap year — is special since it is recognized internationally as Rare Disease Day. Each year, the Pulmonary Hypertension Association (PHA) is an active participant in this important global awareness campaign. Today PHA proudly partners
PHA Promotes PH’s Connection to Heart Disease During American Heart Month
American Heart Month is ending, but the fight to elevate heart health consciousness continues. Throughout February the Pulmonary Hypertension Association (PHA) has been using social media to spread the word about the link between pulmonary hypertension (PH) and heart failure and making heart-healthy choices. PHA followers are using #OurHearts and #PHAssociation on social media